Legend Biotech's Recognition as Foreign Investor of the Year
Legend Biotech Corporation (NASDAQ: LEGN), a leader in the cell therapy sector, recently celebrated a remarkable achievement by being named Foreign Investor of the Year at the 2025 Flanders International Business Awards. This recognition from Flanders Investment & Trade (FIT) underscores the company's continuous commitment to enhancing its cell therapy manufacturing and research and development operations.
Impact of the Award on Local Biotech Ecosystem
The awards, which are hosted by a prominent Flemish government agency, aim to promote international investments that fuel innovation and growth in Flanders. Being honored with the Foreign Investor of the Year award signifies Legend Biotech's long-term dedication to contributing to the local economy, job creation, and the advancement of biotechnology in the region. Notably, the company was also honored with the Startup of the Year award in 2022.
A Testimony of Growth
Ying Huang, the Chief Executive Officer of Legend Biotech, expressed pride in this acknowledgment, highlighting the importance of their partnerships and the company's commitment to pushing the boundaries of cell therapy. The award reflects their ongoing journey of expanding their manufacturing capabilities to provide innovative treatments for patients globally.
Significant Joint Investment
This recent accolade comes alongside a substantial €165 million joint investment with industry giant Johnson & Johnson. This investment will facilitate the expansion of their advanced facility located in Tech Lane Ghent Science Park, making it one of Europe's largest CAR-T manufacturing sites. This expansion also strengthens the Ghent site as the primary European hub for clinical and commercial supply chain efficiency.
Legend Biotech's Workforce Growth
Since launching operations in Ghent just three years ago, the company's workforce has exploded from a mere two employees to over a thousand, showcasing an impressive diversity with team members representing 66 different nationalities. This growth trajectory is expected to continue, with plans for further recruitment in the years to come.
Collaborating for Success
Frederik Buysse, the General Manager at Legend Biotech Belgium, noted that the company’s growth narrative is intrinsically linked to the vibrant Flemish biotech ecosystem. Their strong alliances with governmental bodies and local research institutions like VIB and Ghent University enhance their innovative capabilities and ecosystem synergy.
About Legend Biotech
With a workforce of more than 2,900, Legend Biotech stands as the largest independent cell therapy company and has emerged as a pioneer in revolutionizing cancer treatments. The organization focuses on developing CAR-T cell therapies, notably cilta-cel, in collaboration with Johnson & Johnson. Within the European Union, cilta-cel is marketed under the brand name CARVYKTI®? for treating adult patients with relapsed and refractory multiple myeloma following previous therapies.
Future Innovations and Access
Legend Biotech’s headquarters in the United States is devoted to building a comprehensive cell therapy enterprise, with a focus on ensuring that CAR-T therapies are accessible to a broader patient population while advancing future innovation across their cutting-edge therapy pipeline.
Frequently Asked Questions
What is the significance of the Foreign Investor of the Year award?
The Foreign Investor of the Year award acknowledges companies that significantly contribute to the local economy through investment, job creation, and innovation.
How has Legend Biotech expanded its operations?
Legend Biotech expanded operations through a joint investment of €165 million with Johnson & Johnson, enhancing its manufacturing facility in Ghent, Belgium.
What are CAR-T therapies?
CAR-T therapies are advanced treatments that use modified patient’s T cells to target and kill cancer cells, representing a significant advancement in cancer care.
How many employees does Legend Biotech have?
Legend Biotech employs over 2,900 workers, marking substantial growth in its workforce since opening operations in Belgium.
What role does Flanders play in biotech?
Flanders serves as a dynamic biotech hub that promotes innovation and collaboration, helping companies like Legend Biotech thrive through partnerships with local institutions.
